Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAY 2701439

Next Previous
Search
Drug Profile

BAY 2701439

Alternative Names: BAY2701439; HER2-targetted thorium conjugate- Bayer; Thorium-227 anti-HER2 monoclonal antibody - Bayer; Thorium-227 anti-HER2 monoclonal antibody BAY2701439 - Bayer; Thorium-227 labeled antibody chelator conjugate - Bayer

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Apoptosis stimulants; DNA damage stimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Oct 2023 BAY 2701439 is still in phase I development in Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (IV, Injection) (NCT04147819)
  • 18 Oct 2023 BAY 2701439 is still in phase I development in Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in US (IV, Injection) (NCT04147819)
  • 26 Sep 2023 Bayer completes phase I clinical trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA and UK (IV) (NCT04147819)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top